Literature DB >> 26260080

The factor structure and clinical utility of formal thought disorder in first episode psychosis.

Eric Roche1, John Paul Lyne2, Brian O'Donoghue3, Ricardo Segurado4, Anthony Kinsella5, Ailish Hannigan6, Brendan D Kelly7, Kevin Malone8, Mary Clarke9.   

Abstract

BACKGROUND: Formal thought disorder (FTD) is a core feature of psychosis, however there are gaps in our knowledge about its prevalence and factor structure. We had two aims: first, to establish the factor structure of FTD; second, to explore the clinical utility of dimensions of FTD in order to further the understanding of its nosology.
METHODS: A cross-validation study was undertaken to establish the factor structure of FTD in first episode psychosis (FEP). The relative utility of FTD categories vs. dimensions across diagnostic categories was investigated.
RESULTS: The prevalence of clinically significant FTD in this FEP sample was 21%, although 41% showed evidence of disorganised speech, 20% displayed verbosity and 24% displayed impoverished speech. A 3-factor model was identified as the best fit for FTD, with disorganisation, poverty and verbosity dimensions (GFI=0.99, RMR=0.07). These dimensions of FTD accurately distinguished affective from non-affective diagnostic categories. A categorical approach to FTD assessment was useful in identifying markers of clinical acuteness, as identified by short duration of untreated psychosis (OR=2.94, P<0.01) and inpatient treatment status (OR=3.98, P<0.01).
CONCLUSION: FTD is moderately prevalent and multi-dimensional in FEP. Employing both a dimensional and categorical assessment of FTD gives valuable clinical information, however there may be a need to revise our conceptualisation of the nosology of FTD. The prognostic value of FTD, as well as its neural basis, requires elucidation.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinical utility; Factor structure; Language; Prevalence; Psychosis; Thought disorder

Mesh:

Year:  2015        PMID: 26260080     DOI: 10.1016/j.schres.2015.07.049

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  5 in total

1.  The cognitive aspect of formal thought disorder and its relationship with global social functioning and the quality of life in schizophrenia.

Authors:  Emre Mutlu; Hatice Abaoğlu; Elif Barışkın; Ş Can Gürel; Aygün Ertuğrul; M Kazım Yazıcı; Esra Akı; A Elif Anıl Yağcıoğlu
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2021-01-17       Impact factor: 4.328

2.  Dimensions of Formal Thought Disorder and Their Relation to Gray- and White Matter Brain Structure in Affective and Psychotic Disorders.

Authors:  Frederike Stein; Elena Buckenmayer; Katharina Brosch; Tina Meller; Simon Schmitt; Kai Gustav Ringwald; Julia Katharina Pfarr; Olaf Steinsträter; Verena Enneking; Dominik Grotegerd; Walter Heindel; Susanne Meinert; Elisabeth J Leehr; Hannah Lemke; Katharina Thiel; Lena Waltemate; Alexandra Winter; Tim Hahn; Udo Dannlowski; Andreas Jansen; Igor Nenadić; Axel Krug; Tilo Kircher
Journal:  Schizophr Bull       Date:  2022-06-21       Impact factor: 7.348

3.  Early onset first episode psychosis: dimensional structure of symptoms, clinical subtypes and related neurodevelopmental markers.

Authors:  Maria Giuseppina Petruzzelli; Lucia Margari; Andrea Bosco; Francesco Craig; Roberto Palumbi; Francesco Margari
Journal:  Eur Child Adolesc Psychiatry       Date:  2017-07-26       Impact factor: 4.785

4.  C-reactive protein is associated with severity of thought and language dysfunction in patients with schizophrenia.

Authors:  Hsien-Yuan Lane; Chieh-Hsin Lin; Chun-Hung Chang; Chieh-Yu Liu; Po-Chih Cheng; Shaw-Ji Chen
Journal:  Neuropsychiatr Dis Treat       Date:  2019-09-10       Impact factor: 2.570

5.  Differences in single positive formal thought disorder symptoms between closely matched acute patients with schizophrenia and mania.

Authors:  Tilo Kircher; Frederike Stein; Arne Nagels
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-05-07       Impact factor: 5.270

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.